Ama-Moor Vicky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ama-Moor Vicky has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Agbaya Stéphane Serge Oga
School of Pharmacy, University Félix Houphouet-Boigny, Abidjan, Côte d’Ivoire
1 shared publication - Albert Same-Ekobo
Faculté de Médecine et de Sciences Pharmaceutiques, Douala, Cameroun
1 shared publication - Babacar Faye
Service de Parasitologie-Mycologie, Faculté de Médecine, Université Cheikh Anta Diop, Dakar, Sénégal
1 shared publication - Christiane P Kiki Barro
Department of Parasitology, Faculty of Pharmacy, University of Cocody, Abidjan, Côte d'Ivoire
1 shared publication - Dieynaba Kane
Department of Parasitology, Faculty of Medicine, University Cheikh Anta Diop, Dakar, Sénégal
1 shared publication - Hervé Menan
UFR Faculty of Pharmaceutical and Biological Sciences Laboratory of Parasitology-Mycology Félix Houphouët Boigny University Abidjan BPV 34 Côte d'Ivoire
1 shared publication
Latest Publications
- Open Access
- 8 July 2011
- Published by Springer Nature in Malaria Journal
- Vol. 10 (1) , 185
Comparative study of the efficacy and tolerability of dihydroartemisinin - piperaquine - trimethoprim versus artemether - lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal
The ACT recommended by WHO is very effective and well-tolerated. However, these combinations need to be administered for three days, which may limit adherence to treatment.
- 8 July 2011
- Published by Springer Nature in Malaria Journal
- Vol. 10 (1) , 185
Open AccessComparative study of the efficacy and tolerability of dihydroartemisinin - piperaquine - trimethoprim versus artemether - lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal
The ACT recommended by WHO is very effective and well-tolerated. However, these combinations need to be administered for three days, which may limit adherence to treatment.